TSXV: ATE   CAD ${{ stocks['ATE.V'].LastPrice }}
Last updated: {{ getStockDate(stocks['ATE.V']) }} ET
OTCQB: ATBPF   USD ${{ stocks['ATBPF'].LastPrice }}
Last updated: {{ getStockDate(stocks['ATBPF']) }} ET
CAD ${{ getMCap(stocks['ATE.V']) }}M
MARKET CAP
CAD ${{ stocks['ATE.V'].YearHigh }}/${{ stocks['ATE.V'].YearLow }}
52-WEEK HIGH/LOW
{{ stocks['ATE.V'].AverageDailyVolume3Month }}
AVG. DAILY TRADING VOLUME
14%
INSIDER OWNERSHIP

Corporate Presentation

Learn how Antibe is aiming to change the game in pain and inflammation medicine. Delve into our market opportunity, drug pipeline and the science that underlies our drug platform.

Last updated: August 2020

ANALYST COVERAGE

FIRM                                                                                                 ANALYST

Brookline Capital Markets                                                      Sally A. Yanchus, MBA
Canaccord Genuity Capital Markets                                   Tania Gonsalves, CFA
Echelon Wealth Partners                                                         Douglas Loe, PhD, MBA
Maxim Group                                                                                Jason McCarthy, PhD
Paradigm Capital                                                                        Scott McAuley, PhD

The opinions, forecasts and estimates of these analysts do not represent those of Antibe Therapeutics or its directors.

 

Attention

This is an external link. Click “OK” to continue.

CANCEL OK